Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years
Key takeaways
- Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years Maham Fatima Mon, June 8, 2026 at 5:47 PM GMT+7 2 min read BMRN Bio Marin Pharmaceutical Inc.
- The company highlighted significant progress across its clinical pipeline and commercial operations.
- To support its growth strategy, BioMarin secured ~$3.7 billion in non-convertible debt to fund the Amicus acquisition while maintaining strong operating cash flows of $221 million for the quarter.
Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years Maham Fatima Mon, June 8, 2026 at 5:47 PM GMT+7 2 min read BMRN Bio Marin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most undervalued stocks to buy and hold for 2 years. On May 4, Bio Marin reported financial results for Q1 2026, with total revenues reaching $766 million. Driven by the recent acquisition of Amicus Therapeutics and the addition of GALAFOLD and POMBILITI + OPFOLDA to its portfolio, the company has increased its full-year 2026 revenue guidance to a range of $3.825 to $3.925 billion, representing a year-over-year growth rate of 20%.
The company highlighted significant progress across its clinical pipeline and commercial operations. Key updates included the FDA approval of PALYNZIQ for adolescents with phenylketonuria, the submission of an sNDA for the full approval of VOXZOGO for achondroplasia, and positive clinical data presentations for BMN 351 and VOXZOGO. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) also reported steady revenue growth across its existing enzyme therapy products and a consistent increase in the number of children treated with VOXZOGO.
To support its growth strategy, BioMarin secured ~$3.7 billion in non-convertible debt to fund the Amicus acquisition while maintaining strong operating cash flows of $221 million for the quarter. With total cash reserves of ~$2 billion and upcoming Phase 3 data readouts expected later this year, the company remains focused on scaling its commercial portfolio and advancing its innovation pipeline to drive long-term value for patients and shareholders.